PK
Distinguished in Metastatic Brain Tumor
Check Dr. Priya U. Kumthekar's experience treating your condition:
About Dr. Priya U. Kumthekar

Priya Kumthekar is a Hematologist Oncology specialist and a Neurologist in Chicago, Illinois. Kumthekar has been practicing medicine for over 16 years and is rated as a Distinguished expert by MediFind in the treatment of Metastatic Brain Tumor. She is also highly rated in 25 other conditions, according to our data. Her top areas of expertise are Brain Tumor, Glioblastoma, Glioma, and Astrocytoma. She is licensed to treat patients in Illinois. Kumthekar is currently accepting new patients.

Her clinical research consists of co-authoring 74 peer reviewed articles and participating in 25 clinical trials in the past 15 years. In particular, she has co-authored 10 articles and participated in 1 clinical trial in the study of Metastatic Brain Tumor.

Insurance

MediFind strives to display the most accurate insurance information for every doctor. If you do not see your insurance listed for Dr. Priya U. Kumthekar it is best to call her office and ask if your insurance is accepted.

Accepts Medicare

Call to see if your plan is accepted.
Locations
675 N Saint Clair St, Chicago, IL 60611
Background & Education
Graduate Institution
Northeastern Ohio University College Of Medicine, 2007
Specialties
Hematology Oncology
Neurology
Licenses
Psychiatry & Neurology in IL
Hospital Affiliations
Northwestern Medicine Lake Forest Hospital
Northwestern Medicine Delnor Hospital
Northwestern Medicine Central DuPage Hospital
Northwestern Memorial Hospital
Languages Spoken
English
Dutch
French
Korean
Spanish
Gender
Female
Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Doctors who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.


23 Clinical Trials

A Phase II Study of Checkpoint Blockade Immunotherapy in Patients With Somatically Hypermutated Recurrent WHO Grade 4 Glioma
Phase 1 / 2 Trial of Blood-brain Barrier Opening With an Implantable Ultrasound Device SonoCloud-9 and Treatment With Albumin-bound Paclitaxel and Carboplatin in Patients With Recurrent Glioblastoma
Molecular Analysis for Therapy Choice (MATCH)
Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease
Phase II Trial of SMO/ AKT/ NF2/CDK Inhibitors in Progressive Meningiomas With SMO/ AKT/ NF2/CDK Pathway Mutations
A Phase 1/1b Adaptive Dose Escalation Study of Mycophenolate Mofetil (MMF) in Combination With Standard of Care for Patients With Glioblastoma
Genomically-Guided Treatment Trial in Brain Metastases
A Phase 2, Single Arm, Multi-center, Open Label Trial Combining Optune With Concurrent Bevacizumab in the Setting of Recurrent or Progressive Meningioma
Phase III Intergroup Study of Radiotherapy With Concomitant and Adjuvant Temozolomide Versus Radiotherapy With Adjuvant PCV Chemotherapy in Patients With 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma
A Phase 1/2 Study of Selinexor in Combination With Standard of Care (SoC) Therapy for Newly Diagnosed or Recurrent Glioblastoma
A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation
A Phase II, Open Label, Clinical Trial Of Pre-Surgical and Adjuvant Treatment of Recurrent Malignant Glioma With Tremelimumab and Durvalumab (MEDI4736) Alone and in Combination to Determine Immunologic Changes From Treatment
A Phase II, Multi-center, Open-label Study of a Conditionally Replicative Adenovirus (DNX-2401) With Pembrolizumab (KEYTRUDA®) for Recurrent Glioblastoma or Gliosarcoma (CAPTIVE/KEYNOTE-192)
Phase II Trial of Bevacizumab in Patients With Recurrent or Progressive Meningiomas
A Phase II Trial of Bevacizumab in Patients With Recurrent Solid Tumor Brain Metastases Who Have Failed Whole Brain Radiation Therapy
View 12 Less Clinical Trials -

74 Total Publications

Alliance A071401: Phase II Trial of Focal Adhesion Kinase Inhibition in Meningiomas With Somatic NF2 Mutations.


Save this doctor for later
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find a second opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn more
Similar Doctors
Elite
Elite
Distinguished